| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/03/2002 | EP1219294A1 Melanin concentrating hormone antagonists |
| 07/03/2002 | EP1219292A1 Procedure or manufacturing dry powdered compositions comprising one or several oxygen-containing carotenoids |
| 07/03/2002 | EP1219291A1 Texture masked particles containing an active ingredient |
| 07/03/2002 | EP1219182A2 Better tasting L-amino acid salts and their manufacture |
| 07/03/2002 | EP1219180A1 Cancer chemoprotective food products |
| 07/03/2002 | EP1218889A2 Controlled release compositions comprising nimesulide |
| 07/03/2002 | EP1218747A1 Method for identifying compounds useful in the therapy of bone disorders |
| 07/03/2002 | EP1218544A1 Methods for identifying rna binding compounds |
| 07/03/2002 | EP1218516A2 Method for preparing steroids modified by yeast fermentation |
| 07/03/2002 | EP1218515A2 Regulation with binding cassette transporter protein abc1 |
| 07/03/2002 | EP1218511A1 Antimicrobial compositions |
| 07/03/2002 | EP1218506A1 Traf4 associated cell cycle proteins, compositions and methods of use |
| 07/03/2002 | EP1218494A2 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 07/03/2002 | EP1218493A1 Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof |
| 07/03/2002 | EP1218491A1 Dna encoding a human subunit 5-ht3-c of the 5-ht3 serotonin receptor |
| 07/03/2002 | EP1218412A2 Human g-protein coupled receptor |
| 07/03/2002 | EP1218408A1 32 human secreted proteins |
| 07/03/2002 | EP1218406A1 Nucleic acids and secreted polypeptides encoded thereby |
| 07/03/2002 | EP1218402A1 Novel betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis |
| 07/03/2002 | EP1218401A1 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use |
| 07/03/2002 | EP1218398A1 Antisense modulation of pi3 kinase p110 beta expression |
| 07/03/2002 | EP1218397A1 Attractin-like polynucleotides, polypeptides, and antibodies |
| 07/03/2002 | EP1218395A1 Antisense modulation of x-linked inhibitor of apoptosis expression |
| 07/03/2002 | EP1218393A1 Cell targeting compositions and methods of using the same |
| 07/03/2002 | EP1218383A2 Bicyclic imidazo-5-yl-amine derivatives |
| 07/03/2002 | EP1218382A2 Bicyclic imidazo-3-yl-amine derivatives |
| 07/03/2002 | EP1218381A2 AMINO SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES |
| 07/03/2002 | EP1218380A2 Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring |
| 07/03/2002 | EP1218379A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES |
| 07/03/2002 | EP1218378A2 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives |
| 07/03/2002 | EP1218376A1 Tyrosine kinase inhibitors |
| 07/03/2002 | EP1218375A1 Pharmaceutically active sulfonyl amino acid derivatives |
| 07/03/2002 | EP1218374A1 Pharmaceutically active sulfonamide derivatives |
| 07/03/2002 | EP1218373A2 2-pyrazolin-5-ones as tyrosine kinase inhibitors |
| 07/03/2002 | EP1218372A1 Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| 07/03/2002 | EP1218371A2 Di-substituted iminoheterocyclic compounds |
| 07/03/2002 | EP1218370A2 Quinolyl propyl piperidine derivatives and their use as antibacterial agents |
| 07/03/2002 | EP1218369A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 07/03/2002 | EP1218368A1 COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS |
| 07/03/2002 | EP1218366A2 Method for producing cox-2 inhibitors |
| 07/03/2002 | EP1218361A1 Oxa- and thiazole derivatives useful as antidiabetic and antiobesity agents |
| 07/03/2002 | EP1218360A1 Triazine kinase inhibitors |
| 07/03/2002 | EP1218359A2 Piperazine compounds |
| 07/03/2002 | EP1218358A1 Therapeutic quinazoline compounds |
| 07/03/2002 | EP1218357A1 Quinazoline derivatives |
| 07/03/2002 | EP1218356A1 Quinazoline compounds and pharmaceutical compositions containing them |
| 07/03/2002 | EP1218355A1 Therapeutic quinazoline derivatives |
| 07/03/2002 | EP1218354A1 Quinazoline derivatives and their use as pharmaceuticals |
| 07/03/2002 | EP1218353A1 Quinazoline derivatives |
| 07/03/2002 | EP1218352A1 Benzimidazolone derivatives having mixed serotonine and dopamine receptors affinity |
| 07/03/2002 | EP1218348A2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 07/03/2002 | EP1218347A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 07/03/2002 | EP1218346A1 Pyrazole derivatives |
| 07/03/2002 | EP1218342A2 Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof |
| 07/03/2002 | EP1218341A1 Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
| 07/03/2002 | EP1218339A2 Benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides |
| 07/03/2002 | EP1218335A1 Hydrated n-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride and it's use in pharmaceutical compositions |
| 07/03/2002 | EP1218334A1 Polymorphic n-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]- 4-nitro benzamide hydrochloride |
| 07/03/2002 | EP1218333A1 Anti-inflammatory nitro- and thia- fatty acids |
| 07/03/2002 | EP1218063A2 Pharmaceutical composition containing trichloroacetic acid, 2-oh benzoic acid and menthol for topical application, uses and process for the preparation thereof |
| 07/03/2002 | EP1218039A1 High citrate dialysate and uses thereof |
| 07/03/2002 | EP1218027A2 Composition for stabilizing corneal tissue during or after orthokeratological lens wear |
| 07/03/2002 | EP1218025A1 Use of mullerian inhibiting substance for treating excess androgen states |
| 07/03/2002 | EP1218022A2 Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba |
| 07/03/2002 | EP1218020A1 Treatment of diabetic nephropathy and microalbuminuria |
| 07/03/2002 | EP1218017A2 Combination of a statin and ex-vivo treated blood for treating atherosclerosis |
| 07/03/2002 | EP1218015A2 Pharmaceutical composition of nateglinide and another antidiabetic agent |
| 07/03/2002 | EP1218014A2 Compositions comprising progesterone or progesterone analogs for the treatment of inflammatory conditions |
| 07/03/2002 | EP1218013A2 Phospholipid prodrugs of anti-proliferative drugs |
| 07/03/2002 | EP1218012A2 Use of alprostadil (prostaglandin e1) for producing a medicament for angioneogenesis |
| 07/03/2002 | EP1218011A1 Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses |
| 07/03/2002 | EP1218010A2 1,4-benzothiazepines to treat obesity related disorders |
| 07/03/2002 | EP1218009A1 Quetiapine granules |
| 07/03/2002 | EP1218008A2 New use of 1,2,4-triazolo[1,5-a]pyrimidines |
| 07/03/2002 | EP1218007A1 Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| 07/03/2002 | EP1218006A2 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties |
| 07/03/2002 | EP1218005A2 Vitronectin receptor antagonists |
| 07/03/2002 | EP1218004A2 Use of cell membrane penetrating indigoid bisindole derivatives |
| 07/03/2002 | EP1218003A1 Composition and method for decreasing neurologic symptomatology |
| 07/03/2002 | EP1218002A1 Use of flavone 8-acetic acid in vascular and cardiovascular interventions and acute coronary syndromes |
| 07/03/2002 | EP1218001A1 Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same |
| 07/03/2002 | EP1218000A1 Anti-cancer nitro- and thia-fatty acids |
| 07/03/2002 | EP1217999A2 The use of baclofen in the treatment of alcoholism |
| 07/03/2002 | EP1217998A2 Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence |
| 07/03/2002 | EP1217997A1 A process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine |
| 07/03/2002 | EP1217996A1 Use of xanthophylls, astaxanthin e.g., for treatment of autoimmune diseases, chronic viral and intracellular bacterial infections |
| 07/03/2002 | EP1217995A2 Anti-mycobacterium compositions and methods of preparing and using same |
| 07/03/2002 | EP1217994A2 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis |
| 07/03/2002 | EP1217993A2 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 07/03/2002 | EP1217992A1 Coated solid dosage forms |
| 07/03/2002 | EP1217990A1 Cationic dosper virosomes |
| 07/03/2002 | EP1217983A1 Skincare composition against free radicals |
| 07/03/2002 | EP1217975A1 Using quaternary ammonium salts for transdermal drug delivery |
| 07/03/2002 | EP1217963A1 Devices and methods for treating tissue |
| 07/03/2002 | EP1217902A1 Nutritional compositions which contain non-digestible polysaccharides and use thereof to reduce transport through tight junctions |
| 07/03/2002 | EP1131062A4 Injectable propofol formulations |
| 07/03/2002 | EP1109536B1 New solid dose form of nanoparticulate naproxen |
| 07/03/2002 | EP1077912B1 Novel derivatives of 3,3-diphenylpropylamines |
| 07/03/2002 | EP1063978A4 Method of treating neuroma pain |
| 07/03/2002 | EP1059920B1 Use of alkyl hydrogen fumarates for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis |